Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC Keeping it real board for pro and con discussions -- Ignore unavailable to you. Want to Upgrade?

To: drkaz who wrote (276)	1/20/2016 6:56:08 AM
From: NewMoney_812	1 Recommendation Recommended By Rawnoc Respond to of 326

You know exactly who it is. And how much money has been milked out of sucker investors that have been led astray all the way down from $7 to penny land with this crap. Shame.

To: drkaz who wrote (276)	1/21/2016 6:17:31 PM
From: Rawnoc	Read Replies (1) \| Respond to of 326

What drug were you on when you wrote this laughable nonsense? siliconinvestor.com (1) You ASSume that every single man, woman, and child will buy the drug at full value rather than something based in reality that a relatively much smaller percentage of the people. (2) You call an entire $45 million in mythical sales as net income -- $0 allocated for cost of the drugs or overhead which are already significant. (3) Then you use a P/E ratio static in response to a post using P/S statics. By the way, if you used the laughable ASSumption that everybody with a disease got cured by NNVC, there would be little if anybody left the following year to cure! The 45,000 people per year who get the disease need to get it from UNCURED people for the most part otherwise the numbers diminish to zero. Better ASSumption, yet still wildly optimistic, would be say 25% take the drug so there are still plenty of new and uncured people to keep it spreading. Your $45 million goes down to barely any profit if any at all. It would realistically bring the company a lot closer to break-even at best which is great but it's nowhere near the laughable attempt at analysis in your post. No wonder you're getting your butt handed to you -- Even the basic mathematics of stocks escape you.